Evidence map›Paper›PMID 41800233›Full record

ArticleLancet regional health. Americas2026

Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019.

Kevin L'Espérance, Katherine Lin, Daphne Lichtensztajn, Simon John Christoph Soerensen, Shuchi Gulati, Zhengyi Deng, John T Leppert, David Y Oh, Lori C Sakoda, Samuel L Washington and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kevin L'EspéranceDepartment of Urology, Stanford University School of Medicine, Palo Alto, CA, USA.
Katherine LinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Daphne LichtensztajnDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Simon John Christoph SoerensenDepartment of Urology, Stanford University School of Medicine, Palo Alto, CA, USA.
Shuchi GulatiDivision of Hematology and Oncology, Department of Internal Medicine, University of California Davis, Sacramento, CA, USA.
Zhengyi DengDepartment of Urology, Stanford University School of Medicine, Palo Alto, CA, USA.
John T LeppertDepartment of Urology, Stanford University School of Medicine, Palo Alto, CA, USA.
David Y OhDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Lori C SakodaDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Samuel L WashingtonDepartment of Urology, University of California, San Francisco, San Francisco, CA, USA.
Maxwell V MengDepartment of Urology, University of California, San Francisco, San Francisco, CA, USA.
June M ChanDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Marvin E LangstonDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, CA, USA.
Iona ChengDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Benjamin I ChungDepartment of Urology, Stanford University School of Medicine, Palo Alto, CA, USA.
Rebecca E GraffDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renal cell carcinoma (RCC) incidence and mortality trends in California that reflect contemporary patterns of incidental diagnoses and new treatment advances have not been published, and RCC burden across sociodemographic groups remains unclear. We sought to investigate the incidence and mortality rates of first RCC in individuals aged 20 and older in California from 1988 through 2019, including overall trends and by sociodemographic factors. Methods: Data were obtained from the California Cancer Registry. We calculated age-adjusted incidence and mortality rates and rate ratios (where relevant) of RCC overall and by sex, age, race and ethnicity, and neighborhood socioeconomic status (nSES). Joinpoint regression was used to estimate annual percent rate changes in incidence and mortality rates across time periods. Findings: From 1988 through 2019, we identified 90,659 incident RCC cases, of which 62.9% were localized at diagnosis, and 37,069 RCC-related deaths. Incidence was higher in males than females, among American Indian/Alaska Native, Hispanic, and non-Hispanic Black individuals, and in lower-nSES areas. Incidence rose over time, with steeper increases among Hispanic and non-Hispanic Black populations and in the lowest nSES groups. Although mortality declined overall, disparities persisted, with Hispanic and non-Hispanic Black individuals experiencing higher mortality than non-Hispanic White individuals. Interpretation: RCC remains a significant public health concern in California, with disparities by race, ethnicity, and nSES widening over time. This underscores the relevance of RCC as a health equity issue and the need for targeted public health action and equity-focused research. Funding: This study utilized publicly accessible data from infrastructure supported by the California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention.

Indexed as

CaliforniaIncidenceKidney cancerMortalityRenal cell carcinomaTrends

Identifiers

PMID41800233
PMCPMC12964298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.